H3 Biomedicine

H3 Biomedicine, Selvita collaborate

Monday, September 23, 2013 01:39 PM

H3 Biomedicine, a Cambridge, Mass.-based biopharmaceutical company specializing in  discovering and developing precision oncology treatments, and Selvita, a drug discovery company in Eastern Europe, have entered into a strategic collaboration to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and feasibility of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets.

More... »

H3 Biomedicine, Selvita collaborate

Wednesday, September 18, 2013 01:41 PM

H3 Biomedicine, a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita, a drug discovery company in Eastern Europe, have are collaborating to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and druggability of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets.

More... »

H3 Biomedicine, BGI Announce to develop, share cancer genomic sequencing data

Friday, March 22, 2013 03:33 PM

H3 Biomedicine, a biopharmaceutical company specializing in oncology treatments, and BGI, the largest genomics organization in the world, have entered into a partnership to sequence and publish genomic data from pre-clinical cancer models.

More... »

H3 Biomedicine opens headquarters in Cambridge, Massachusetts

Friday, December 2, 2011 05:10 PM

H3 Biomedicine has opened a new headquarters and 24,000 square feet of state-of-the-art laboratory space in Cambridge, Massachusetts. Over the next year, the company plans to increase its staff to 70 people and further expand into more laboratory space within its building as it continues to pursue its mission to fulfill the promise of personalized cancer medicine.

More... »

H3 Biomedicine names CEO

Thursday, November 3, 2011 10:27 AM

H3 Biomedicine has named Markus Warmuth, M.D., president and chief executive officer, effective immediately.

More... »